+ADw-html xmlns:v+AD0AIg-urn:schemas-microsoft-com:vml+ACI-
xmlns:o+AD0AIg-urn:schemas-microsoft-com:office:office+ACI-
xmlns:w+AD0AIg-urn:schemas-microsoft-com:office:word+ACI-
xmlns+AD0AIg-http://www.w3.org/TR/REC-html40+ACIAPg- +ADw-head+AD4-
+ADw-meta http-equiv+AD0-Content-Type content+AD0AIg-text/html+ADs-
charset+AD0-utf-7+ACIAPg- +ADw-meta name+AD0-ProgId
content+AD0-Word.Document+AD4- +ADw-meta name+AD0-Generator
content+AD0AIg-Microsoft Word 11+ACIAPg- +ADw-meta
name+AD0-Originator content+AD0AIg-Microsoft Word 11+ACIAPg-
+ADw-link rel+AD0-File-List
href+AD0AIg-dex1048+AF8-31+AF8-files/filelist.xml+ACIAPg- +ADw-link
rel+AD0-Edit-Time-Data
href+AD0AIg-dex1048+AF8-31+AF8-files/editdata.mso+ACIAPg-
+ADwAIQ---+AFs-if +ACE-mso+AF0APg- +ADw-style+AD4- v+AFw-:+ACo-
+AHs-behavior:url(+ACM-default+ACM-VML)+ADsAfQ- o+AFw-:+ACo-
+AHs-behavior:url(+ACM-default+ACM-VML)+ADsAfQ- w+AFw-:+ACo-
+AHs-behavior:url(+ACM-default+ACM-VML)+ADsAfQ- .shape
+AHs-behavior:url(+ACM-default+ACM-VML)+ADsAfQ- +ADw-/style+AD4-
+ADwAIQBb-endif+AF0---+AD4- +ADw-title+AD4-First Amendment to
Collaboration Agreement, effective as of February 28,
2007+ADw-/title+AD4- +ADwAIQ---+AFs-if gte mso 9+AF0APgA8-xml+AD4-
+ADw-o:DocumentProperties+AD4-
+ADw-o:Author+AD4-RPSPPSVC+ADw-/o:Author+AD4-
+ADw-o:Template+AD4-Normal+ADw-/o:Template+AD4-
+ADw-o:LastAuthor+AD4-rpsppsvc+ADw-/o:LastAuthor+AD4-
+ADw-o:Revision+AD4-2+ADw-/o:Revision+AD4-
+ADw-o:TotalTime+AD4-0+ADw-/o:TotalTime+AD4-
+ADw-o:Created+AD4-2007-05-21T09:42:00Z+ADw-/o:Created+AD4-
+ADw-o:LastSaved+AD4-2007-05-21T09:42:00Z+ADw-/o:LastSaved+AD4-
+ADw-o:Pages+AD4-1+ADw-/o:Pages+AD4-
+ADw-o:Words+AD4-2570+ADw-/o:Words+AD4-
+ADw-o:Characters+AD4-14654+ADw-/o:Characters+AD4-
+ADw-o:Company+AD4-Practice Technologies, Inc.+ADw-/o:Company+AD4-
+ADw-o:Lines+AD4-122+ADw-/o:Lines+AD4-
+ADw-o:Paragraphs+AD4-34+ADw-/o:Paragraphs+AD4-
+ADw-o:CharactersWithSpaces+AD4-17190+ADw-/o:CharactersWithSpaces+AD4-
+ADw-o:Version+AD4-11.8132+ADw-/o:Version+AD4-
+ADw-/o:DocumentProperties+AD4-
+ADw-/xml+AD4APAAhAFs-endif+AF0---+AD4APAAh---+AFs-if gte mso
9+AF0APgA8-xml+AD4- +ADw-w:WordDocument+AD4-
+ADw-w:ValidateAgainstSchemas/+AD4-
+ADw-w:SaveIfXMLInvalid+AD4-false+ADw-/w:SaveIfXMLInvalid+AD4-
+ADw-w:IgnoreMixedContent+AD4-false+ADw-/w:IgnoreMixedContent+AD4-
+ADw-w:AlwaysShowPlaceholderText+AD4-false+ADw-/w:AlwaysShowPlaceholderText+AD4-
+ADw-w:BrowserLevel+AD4-MicrosoftInternetExplorer4+ADw-/w:BrowserLevel+AD4-
+ADw-/w:WordDocument+AD4-
+ADw-/xml+AD4APAAhAFs-endif+AF0---+AD4APAAh---+AFs-if gte mso
9+AF0APgA8-xml+AD4- +ADw-w:LatentStyles
DefLockedState+AD0AIg-false+ACI-
LatentStyleCount+AD0AIg-156+ACIAPg- +ADw-/w:LatentStyles+AD4-
+ADw-/xml+AD4APAAhAFs-endif+AF0---+AD4- +ADw-style+AD4- +ADwAIQ---
/+ACo- Style Definitions +ACo-/ p.MsoNormal, li.MsoNormal,
div.MsoNormal +AHs-mso-style-parent:+ACIAIgA7- margin:0in+ADs-
margin-bottom:.0001pt+ADs- mso-pagination:widow-orphan+ADs-
font-size:12.0pt+ADs- font-family:+ACI-Times New Roman+ACIAOw-
mso-fareast-font-family:+ACI-Times New Roman+ACIAOwB9- p
+AHs-mso-margin-top-alt:auto+ADs- margin-right:0in+ADs-
mso-margin-bottom-alt:auto+ADs- margin-left:0in+ADs-
mso-pagination:widow-orphan+ADs- font-size:12.0pt+ADs-
font-family:+ACI-Times New Roman+ACIAOw-
mso-fareast-font-family:+ACI-Times New Roman+ACIAOwB9- +AEA-page
Section1 +AHs-size:8.5in 11.0in+ADs- margin:1.0in 1.25in 1.0in
1.25in+ADs- mso-header-margin:.5in+ADs- mso-footer-margin:.5in+ADs-
mso-paper-source:0+ADsAfQ- div.Section1 +AHs-page:Section1+ADsAfQ-
--+AD4- +ADw-/style+AD4- +ADwAIQ---+AFs-if gte mso 10+AF0APg-
+ADw-style+AD4- /+ACo- Style Definitions +ACo-/
table.MsoNormalTable +AHs-mso-style-name:+ACI-Table Normal+ACIAOw-
mso-tstyle-rowband-size:0+ADs- mso-tstyle-colband-size:0+ADs-
mso-style-noshow:yes+ADs- mso-style-parent:+ACIAIgA7-
mso-padding-alt:0in 5.4pt 0in 5.4pt+ADs- mso-para-margin:0in+ADs-
mso-para-margin-bottom:.0001pt+ADs-
mso-pagination:widow-orphan+ADs- font-size:10.0pt+ADs-
font-family:+ACI-Times New Roman+ACIAOw-
mso-ansi-language:+ACM-0400+ADs-
mso-fareast-language:+ACM-0400+ADs-
mso-bidi-language:+ACM-0400+ADsAfQ- +ADw-/style+AD4-
+ADwAIQBb-endif+AF0---+AD4APAAh---+AFs-if gte mso
9+AF0APgA8-xml+AD4- +ADw-o:shapedefaults v:ext+AD0AIg-edit+ACI-
spidmax+AD0AIg-2050+ACI-/+AD4-
+ADw-/xml+AD4APAAhAFs-endif+AF0---+AD4APAAh---+AFs-if gte mso
9+AF0APgA8-xml+AD4- +ADw-o:shapelayout v:ext+AD0AIg-edit+ACIAPg-
+ADw-o:idmap v:ext+AD0AIg-edit+ACI- data+AD0AIg-1+ACI-/+AD4-
+ADw-/o:shapelayout+AD4APA-/xml+AD4APAAhAFs-endif+AF0---+AD4-
+ADw-/head+AD4- +ADw-body bgcolor+AD0-white lang+AD0-EN-US
style+AD0-'tab-interval:.5in'+AD4- +ADw-div class+AD0-Section1+AD4-
+ADw-p style+AD0-'margin:0in+ADs-margin-bottom:.0001pt'+AD4APA-span
style+AD0-'font-size:10.0pt'+AD4AWwAqAF0- indicates that a
confidential portion of the text of this agreement has been
omitted. +ADw-/span+AD4APA-/p+AD4- +ADw-p align+AD0-right
style+AD0-'margin-top:9.0pt+ADs-margin-right:0in+ADs-margin-bottom:0in+ADs-
margin-left:0in+ADs-margin-bottom:.0001pt+ADs-text-align:right'+AD4APA-b+AD4APA-span
style+AD0-'font-size:10.0pt'+AD4-Exhibit 10.48
+ADw-/span+AD4APA-/b+AD4APA-/p+AD4- +ADw-p align+AD0-center
style+AD0-'margin-top:9.0pt+ADs-margin-right:0in+ADs-margin-bottom:0in+ADs-
margin-left:0in+ADs-margin-bottom:.0001pt+ADs-text-align:center'+AD4APA-b+AD4APA-u+AD4APA-span
style+AD0-'font-size:10.0pt'+AD4-FIRST AMENDMENT TO COLLABORATION
AGREEMENT +ADw-/span+AD4APA-/u+AD4APA-/b+AD4APA-/p+AD4- +ADw-p
style+AD0-'margin-top:9.0pt+ADs-margin-right:0in+ADs-margin-bottom:0in+ADs-margin-left:0in+ADs-
margin-bottom:.0001pt+ADs-text-indent:24.5pt'+AD4APA-span
style+AD0-'font-size:10.0pt'+AD4-This First Amendment to
Collaboration Agreement (this +IBwAPA-u+AD4-First
Amendment+ADw-/u+AD4gHQ-) is effective as of
February+ACY-nbsp+ADs-28, 2007 and is made by and between Takeda
Pharmaceutical Company Limited, a Japanese corporation having
offices at 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645, Japan
(hereinafter +IBwAPA-u+AD4-Takeda+ADw-/u+AD4gHQ-)+ADs- and XOMA
(US) LLC, a Delaware limited liability company having offices at
2910 Seventh Street, Berkeley, California 94710, USA (hereinafter
+IBwAPA-u+AD4-XOMA+ADw-/u+AD4gHQ-). +ADw-/span+AD4APA-/p+AD4-
+ADw-p align+AD0-center
style+AD0-'margin-top:13.5pt+ADs-margin-right:0in+ADs-margin-bottom:0in+ADs-
margin-left:0in+ADs-margin-bottom:.0001pt+ADs-text-align:center'+AD4APA-span
style+AD0-'font-size:10.0pt'+AD4-BACKGROUND
+ADw-/span+AD4APA-/p+AD4- +ADw-p
style+AD0-'margin-top:9.0pt+ADs-margin-right:0in+ADs-margin-bottom:0in+ADs-margin-left:0in+ADs-
margin-bottom:.0001pt+ADs-text-indent:24.5pt'+AD4APA-span
style+AD0-'font-size:10.0pt'+AD4-A. XOMA and Takeda entered into a
certain collaboration agreement dated as of
November+ACY-nbsp+ADs-1, 2006 (the
+IBwAPA-u+AD4-Agreement+ADw-/u+AD4gHQ-). +ADw-/span+AD4APA-/p+AD4-
+ADw-p
style+AD0-'margin-top:9.0pt+ADs-margin-right:0in+ADs-margin-bottom:0in+ADs-margin-left:0in+ADs-
margin-bottom:.0001pt+ADs-text-indent:24.5pt'+AD4APA-span
style+AD0-'font-size:10.0pt'+AD4-B. XOMA and Takeda wish to amend
the Agreement to broaden the relationship as specified herein.
+ADw-/span+AD4APA-/p+AD4- +ADw-p
style+AD0-'margin-top:9.0pt+ADs-margin-right:0in+ADs-margin-bottom:0in+ADs-margin-left:0in+ADs-
margin-bottom:.0001pt+ADs-text-indent:24.5pt'+AD4APA-span
style+AD0-'font-size:10.0pt'+AD4-C. Terms which are defined in the
Agreement shall have the same meanings when used in this First
Amendment, unless a different definition is given herein.
+ADw-/span+AD4APA-/p+AD4- +ADw-p
style+AD0-'margin-top:9.0pt+ADs-margin-right:0in+ADs-margin-bottom:0in+ADs-margin-left:0in+ADs-
margin-bottom:.0001pt+ADs-text-indent:24.5pt'+AD4APA-span
style+AD0-'font-size:10.0pt'+AD4-NOW, THEREFORE, in consideration
of the premises and of the mutual covenants and agreements
contained herein, and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, XOMA
and Takeda agree as follows: +ADw-/span+AD4APA-/p+AD4- +ADw-p
style+AD0-'margin-top:9.0pt+ADs-margin-right:0in+ADs-margin-bottom:0in+ADs-margin-left:0in+ADs-
margin-bottom:.0001pt+ADs-text-indent:24.5pt'+AD4APA-span
style+AD0-'font-size:10.0pt'+AD4-Section+ACY-nbsp+ADs-1.
+ADw-u+AD4-Amendments+ADw-/u+AD4-. Pursuant to
Section+ACY-nbsp+ADs-14.9 of the Agreement,
+ADw-/span+AD4APA-/p+AD4- +ADw-p
style+AD0-'margin-top:9.0pt+ADs-margin-right:0in+ADs-margin-bottom:0in+ADs-margin-left:0in+ADs-
margin-bottom:.0001pt+ADs-text-indent:24.5pt'+AD4APA-span
style+AD0-'font-size:10.0pt'+AD4-(a) Section+ACY-nbsp+ADs-1.17 of
the Agreement is hereby amended and restated in its entirety to
read as follows: +ADw-/span+AD4APA-/p+AD4- +ADw-p
style+AD0-'margin-top:9.0pt+ADs-margin-right:0in+ADs-margin-bottom:0in+ADs-margin-left:0in+ADs-
margin-bottom:.0001pt+ADs-text-indent:24.5pt'+AD4APA-span
style+AD0-'font-size:10.0pt'+AD4gHCAcADw-u+AD4-Chiron Exclusivity
Period+ADw-/u+AD4gHQ- shall mean the exclusivity period provided
for in Section+ACY-nbsp+ADs-3.2 of the May+ACY-nbsp+ADs-26, 2005
Research, Development and Commercialization Agreement between
Chiron Corporation and XOMA (the +IBwAPA-u+AD4-Chiron
Agreement+ADw-/u+AD4gHQ-). The Chiron Exclusivity Period expired on
February+ACY-nbsp+ADs-27, 2007.+IB0AOw- +ADw-/span+AD4APA-/p+AD4-
+ADw-p
style+AD0-'margin-top:9.0pt+ADs-margin-right:0in+ADs-margin-bottom:0in+ADs-margin-left:0in+ADs-
margin-bottom:.0001pt+ADs-text-indent:24.5pt'+AD4APA-span
style+AD0-'font-size:10.0pt'+AD4-(b) Section+ACY-nbsp+ADs-1.38 of
the Agreement is hereby amended and restated in its entirety to
read as follows: +ADw-/span+AD4APA-/p+AD4- +ADw-p
style+AD0-'margin-top:9.0pt+ADs-margin-right:0in+ADs-margin-bottom:0in+ADs-margin-left:0in+ADs-
margin-bottom:.0001pt+ADs-text-indent:24.5pt'+AD4APA-span
style+AD0-'font-size:10.0pt'+AD4gHCAcADw-u+AD4-Field+ADw-/u+AD4gHQ-
means any and all uses including but not limited to the diagnosis,
prevention, control or treatment of Cancer.+IB0AOw-
+ADw-/span+AD4APA-/p+AD4- +ADw-p
style+AD0-'margin-top:9.0pt+ADs-margin-right:0in+ADs-margin-bottom:0in+ADs-margin-left:0in+ADs-
margin-bottom:.0001pt+ADs-text-indent:24.5pt'+AD4APA-span
style+AD0-'font-size:10.0pt'+AD4-(c) the first sentence of
Section+ACY-nbsp+ADs-2.1.1 of the Agreement is hereby amended and
restated in its entirety to read as follows:
+ADw-/span+AD4APA-/p+AD4- +ADw-p
style+AD0-'margin-top:9.0pt+ADs-margin-right:0in+ADs-margin-bottom:0in+ADs-margin-left:0in+ADs-
margin-bottom:.0001pt'+AD4APA-span
style+AD0-'font-size:10.0pt'+AD4gHA-The Parties intend to carry out
multiple programs in which Takeda and XOMA will collaborate to
identify and characterize Program Antibodies and to carry out the
Research and Development and Manufacturing of Antibody Products
that act through Collaboration Targets for use in the Field (the
+IBwAPA-u+AD4-Collaboration+ADw-/u+AD4gHQ-), consistent with the
objectives set forth in the applicable Plan(s).+IB0AOw-
+ADw-/span+AD4APA-/p+AD4- +ADw-div class+AD0-MsoNormal
align+AD0-center style+AD0-'text-align:center'+AD4- +ADw-hr
size+AD0-3 width+AD0AIg-100+ACUAIg- noshade
color+AD0AIgAj-999999+ACI- align+AD0-center+AD4- +ADw-/div+AD4-
+ADw-p
style+AD0-'margin:0in+ADs-margin-bottom:.0001pt+ADs-text-indent:24.5pt'+AD4APA-span
style+AD0-'font-size:10.0pt'+AD4-(d) Section+ACY-nbsp+ADs-2.1.3.2
of the Agreement is hereby replaced in its entirety to read as
follows: +ADw-/span+AD4APA-/p+AD4- +ADw-p
style+AD0-'margin-top:9.0pt+ADs-margin-right:0in+ADs-margin-bottom:0in+ADs-margin-left:0in+ADs-
margin-bottom:.0001pt'+AD4APA-span
style+AD0-'font-size:10.0pt'+AD4gHA-XOMA agrees that following the
Effective Date, the provisions of any new antibody research and
development collaboration agreement between XOMA and a Third Party,
or any modification to any existing such agreement, that provides
for exclusivity as between the parties thereto with respect to
matters other than the specific Target(s) covered thereby (e.g.,
with respect to the field(s) of use covered thereby) will not
limit, or will expressly exclude, XOMA+IBk-s ability to accept
Proposed Targets as Collaboration Targets in accordance with the
explicit terms of this Agreement.+IB0AOw- +ADw-/span+AD4APA-/p+AD4-
+ADw-p
style+AD0-'margin-top:9.0pt+ADs-margin-right:0in+ADs-margin-bottom:0in+ADs-margin-left:0in+ADs-
margin-bottom:.0001pt+ADs-text-indent:24.5pt'+AD4APA-span
style+AD0-'font-size:10.0pt'+AD4-(e) the second sentence of
Section+ACY-nbsp+ADs-2.2.2 of the Agreement, which states:
+ADw-/span+AD4APA-/p+AD4- +ADw-p
style+AD0-'margin-top:9.0pt+ADs-margin-right:0in+ADs-margin-bottom:0in+ADs-margin-left:0in+ADs-
margin-bottom:.0001pt'+AD4APA-span
style+AD0-'font-size:10.0pt'+AD4gHA-During the period +AFsAKgBd-,
Takeda may request XOMA+IBk-s consent (which consent shall not be
unreasonably withheld or delayed) to submit additional Proposed
Targets to the Escrow Agent, for consideration as proposed
Collaboration Targets by sending the form attached hereto as
+ADw-u+AD4-Schedule 2.2.2+ADw-/u+AD4-.+IB0-
+ADw-/span+AD4APA-/p+AD4- +ADw-p
style+AD0-'margin-top:9.0pt+ADs-margin-right:0in+ADs-margin-bottom:0in+ADs-margin-left:0in+ADs-
margin-bottom:.0001pt'+AD4APA-span
style+AD0-'font-size:10.0pt'+AD4-is hereby amended and restated in
its entirety to read as follows: +ADw-/span+AD4APA-/p+AD4- +ADw-p
style+AD0-'margin-top:9.0pt+ADs-margin-right:0in+ADs-margin-bottom:0in+ADs-margin-left:0in+ADs-
margin-bottom:.0001pt'+AD4APA-span
style+AD0-'font-size:10.0pt'+AD4gHA-During the period +AFsAKgBd-,
Takeda may request XOMA+IBk-s consent (which consent shall not be
unreasonably withheld or delayed) to submit additional Proposed
Targets to the Escrow Agent, for consideration as proposed
Collaboration Targets by sending the form attached hereto as
+ADw-u+AD4-Schedule 2.2.2+ADw-/u+AD4-.+IB0AOw-
+ADw-/span+AD4APA-/p+AD4- +ADw-p
style+AD0-'margin-top:9.0pt+ADs-margin-right:0in+ADs-margin-bottom:0in+ADs-margin-left:0in+ADs-
margin-bottom:.0001pt+ADs-text-indent:24.5pt'+AD4APA-span
style+AD0-'font-size:10.0pt'+AD4-(f) the fifth sentence of
Section+ACY-nbsp+ADs-2.2.5.1 of the Agreement, which states:
+ADw-/span+AD4APA-/p+AD4- +ADw-p
style+AD0-'margin-top:9.0pt+ADs-margin-right:0in+ADs-margin-bottom:0in+ADs-margin-left:0in+ADs-
margin-bottom:.0001pt'+AD4APA-span
style+AD0-'font-size:10.0pt'+AD4gHA-XOMA may elect to reject such
Proposed Target in the event that +AFsAKgBd-.+IB0-
+ADw-/span+AD4APA-/p+AD4- +ADw-p
style+AD0-'margin-top:9.0pt+ADs-margin-right:0in+ADs-margin-bottom:0in+ADs-margin-left:0in+ADs-
margin-bottom:.0001pt'+AD4APA-span
style+AD0-'font-size:10.0pt'+AD4-is hereby amended and restated in
its entirety to read as follows: +ADw-/span+AD4APA-/p+AD4- +ADw-p
style+AD0-'margin-top:9.0pt+ADs-margin-right:0in+ADs-margin-bottom:0in+ADs-margin-left:0in+ADs-
margin-bottom:.0001pt'+AD4APA-span
style+AD0-'font-size:10.0pt'+AD4gHA-XOMA may elect to reject such
Proposed Target in the event that +AFsAKgBd-.+IB0AOw-
+ADw-/span+AD4APA-/p+AD4- +ADw-p
style+AD0-'margin-top:9.0pt+ADs-margin-right:0in+ADs-margin-bottom:0in+ADs-margin-left:0in+ADs-
margin-bottom:.0001pt+ADs-text-indent:24.5pt'+AD4APA-span
style+AD0-'font-size:10.0pt'+AD4-(g) the following Section is
hereby incorporated into the Agreement as
Section+ACY-nbsp+ADs-2.2.5.2. Sections 2.2.5.2, 2.2.5.3 and 2.2.5.4
of the Agreement are hereby renumbered as Sections 2.2.5.3, 2.2.5.4
and 2.2.5.5, accordingly: +ADw-/span+AD4APA-/p+AD4- +ADw-p
style+AD0-'margin-top:9.0pt+ADs-margin-right:0in+ADs-margin-bottom:0in+ADs-margin-left:0in+ADs-
margin-bottom:.0001pt+ADs-text-indent:24.5pt'+AD4APA-span
style+AD0-'font-size:10.0pt'+AD4gHA-2.2.5.2 On
February+ACY-nbsp+ADs-26, 2007, XOMA proposed to Takeda that
+AFsAKgBd- be treated as the second Collaboration Target for
purposes of this Agreement. With this background, the Parties agree
that, notwithstanding anything contained in this Agreement, as
amended by the First Amendment to Collaboration Agreement effective
as of February+ACY-nbsp+ADs-28, 2007 (the +IBwAPA-u+AD4-First
Amendment+ADw-/u+AD4gHQ-), to the contrary:
+ADw-/span+AD4APA-/p+AD4- +ADw-p
style+AD0-'margin:0in+ADs-margin-bottom:.0001pt'+AD4APA-span
style+AD0-'font-size:9.0pt'+AD4AJg-nbsp+ADsAPA-o:p+AD4APA-/o:p+AD4APA-/span+AD4APA-/p+AD4-
+ADw-table class+AD0-MsoNormalTable border+AD0-0 cellspacing+AD0-0
cellpadding+AD0-0 width+AD0AIg-100+ACUAIg-
style+AD0-'width:100.0+ACUAOw-border-collapse:collapse+ADs-mso-padding-alt:0in
0in 0in 0in'+AD4- +ADw-tr
style+AD0-'mso-yfti-irow:0+ADs-mso-yfti-firstrow:yes+ADs-mso-yfti-lastrow:yes'+AD4-
+ADw-td width+AD0AIg-4+ACUAIg- valign+AD0-top
style+AD0-'width:4.0+ACUAOw-padding:0in 0in 0in 0in'+AD4- +ADw-p
class+AD0-MsoNormal+AD4APA-span
style+AD0-'font-size:10.0pt'+AD4-(a)+ADw-/span+AD4APA-/p+AD4-
+ADw-/td+AD4- +ADw-td valign+AD0-top style+AD0-'padding:0in 0in 0in
0in'+AD4- +ADw-p class+AD0-MsoNormal+AD4APA-span
style+AD0-'font-size:10.0pt'+AD4AWwAqAF0- shall be deemed, as of
the effective date of the First Amendment, the second Collaboration
Target+ADs- +ADw-/span+AD4APA-/p+AD4- +ADw-/td+AD4- +ADw-/tr+AD4-
+ADw-/table+AD4- +ADw-p
style+AD0-'margin:0in+ADs-margin-bottom:.0001pt'+AD4APA-span
style+AD0-'font-size:7.5pt'+AD4AJg-nbsp+ADsAPA-/span+AD4APA-/p+AD4-
+ADw-p align+AD0-center
style+AD0-'margin:0in+ADs-margin-bottom:.0001pt+ADs-text-align:center'+AD4APA-span
style+AD0-'font-size:10.0pt'+AD4--2- +ADw-/span+AD4APA-/p+AD4-
+ADw-div class+AD0-MsoNormal align+AD0-center
style+AD0-'text-align:center'+AD4- +ADw-hr size+AD0-3
width+AD0AIg-100+ACUAIg- noshade color+AD0AIgAj-999999+ACI-
align+AD0-center+AD4- +ADw-/div+AD4- +ADw-table
class+AD0-MsoNormalTable border+AD0-0 cellspacing+AD0-0
cellpadding+AD0-0 width+AD0AIg-100+ACUAIg-
style+AD0-'width:100.0+ACUAOw-border-collapse:collapse+ADs-mso-padding-alt:0in
0in 0in 0in'+AD4- +ADw-tr
style+AD0-'mso-yfti-irow:0+ADs-mso-yfti-firstrow:yes+ADs-mso-yfti-lastrow:yes'+AD4-
+ADw-td width+AD0AIg-4+ACUAIg- valign+AD0-top
style+AD0-'width:4.0+ACUAOw-padding:0in 0in 0in 0in'+AD4- +ADw-p
class+AD0-MsoNormal+AD4APA-span
style+AD0-'font-size:10.0pt'+AD4-(b)+ADw-/span+AD4APA-/p+AD4-
+ADw-/td+AD4- +ADw-td valign+AD0-top style+AD0-'padding:0in 0in 0in
0in'+AD4- +ADw-p class+AD0-MsoNormal+AD4APA-span
style+AD0-'font-size:10.0pt'+AD4-within +AFsAKgBd- after the
effective date of the First Amendment, the Parties shall prepare
and agree (or conclude that they cannot agree) on an initial
R+ACY-amp+ADs-D Plan for +AFsAKgBd- as the second Collaboration
Target, and during the course of such preparation, counsel for each
of the Parties will discuss any intellectual property rights owned
or controlled by any Third Party known to such Party that relate to
+AFsAKgBd- and are relevant to the therapeutic Antibodies+ADs- and
+ADw-/span+AD4APA-/p+AD4- +ADw-/td+AD4- +ADw-/tr+AD4-
+ADw-/table+AD4- +ADw-p
style+AD0-'margin:0in+ADs-margin-bottom:.0001pt'+AD4APA-span
style+AD0-'font-size:4.5pt'+AD4AJg-nbsp+ADsAPA-o:p+AD4APA-/o:p+AD4APA-/span+AD4APA-/p+AD4-
+ADw-table class+AD0-MsoNormalTable border+AD0-0 cellspacing+AD0-0
cellpadding+AD0-0 width+AD0AIg-100+ACUAIg-
style+AD0-'width:100.0+ACUAOw-border-collapse:collapse+ADs-mso-padding-alt:0in
0in 0in 0in'+AD4- +ADw-tr
style+AD0-'mso-yfti-irow:0+ADs-mso-yfti-firstrow:yes+ADs-mso-yfti-lastrow:yes'+AD4-
+ADw-td width+AD0AIg-4+ACUAIg- valign+AD0-top
style+AD0-'width:4.0+ACUAOw-padding:0in 0in 0in 0in'+AD4- +ADw-p
class+AD0-MsoNormal+AD4-+ADw-span
style+AD0-'font-size:10.0pt'+AD4-(c)+ADw-/span+AD4APA-/p+AD4-
+ADw-/td+AD4- +ADw-td valign+AD0-top style+AD0-'padding:0in 0in 0in
0in'+AD4- +ADw-p class+AD0-MsoNormal+AD4APA-span
style+AD0-'font-size:10.0pt'+AD4-in the event that such initial
R+ACY-amp+ADs-D Plan for +AFsAKgBd- as the second Collaboration
Target is not mutually agreed within the said +AFsAKgBd- period,
then +AFsAKgBd- shall lose its status as a Collaboration Target
retroactively as of the effective date of the First Amendment and,
for purposes of Section+ACY-nbsp+ADs-7.3.5 (as amended by the First
Amendment), +AFsAKgBd- shall be deemed to be a Proposed Target
named by Takeda but rejected by XOMA for reasons other than those
set forth in the last paragraph of
Section+ACY-nbsp+ADs-7.3.5.+IB0AOw- +ADw-/span+AD4APA-/p+AD4-
+ADw-/td+AD4- +ADw-/tr+AD4- +ADw-/table+AD4- +ADw-p
style+AD0-'margin-top:9.0pt+ADs-margin-right:0in+ADs-margin-bottom:0in+ADs-margin-left:0in+ADs-
margin-bottom:.0001pt+ADs-text-indent:24.5pt'+AD4APA-span
style+AD0-'font-size:10.0pt'+AD4-(h) Section+ACY-nbsp+ADs-7.1 of
the Agreement is hereby amended and restated in its entirety to
read as follows: +ADw-/span+AD4APA-/p+AD4- +ADw-p
style+AD0-'margin-top:9.0pt+ADs-margin-right:0in+ADs-margin-bottom:0in+ADs-margin-left:0in+ADs-
margin-bottom:.0001pt'+AD4APA-span
style+AD0-'font-size:10.0pt'+AD4gHAA8-u+AD4-Upfront
Fees+ADw-/u+AD4-. Takeda shall pay XOMA in cash
+ADw-/span+AD4APA-/p+AD4- +ADw-p
style+AD0-'margin:0in+ADs-margin-bottom:.0001pt'+AD4APA-span
style+AD0-'font-size:4.5pt'+AD4AJg-nbsp+ADsAPA-o:p+AD4APA-/o:p+AD4APA-/span+AD4APA-/p+AD4-
+ADw-table class+AD0-MsoNormalTable border+AD0-0 cellspacing+AD0-0
cellpadding+AD0-0 width+AD0AIg-100+ACUAIg-
style+AD0-'width:100.0+ACUAOw-border-collapse:collapse+ADs-mso-padding-alt:0in
0in 0in 0in'+AD4- +ADw-tr
style+AD0-'mso-yfti-irow:0+ADs-mso-yfti-firstrow:yes+ADs-mso-yfti-lastrow:yes'+AD4-
+ADw-td width+AD0AIg-4+ACUAIg- valign+AD0-top
style+AD0-'width:4.0+ACUAOw-padding:0in 0in 0in 0in'+AD4- +ADw-p
class+AD0-MsoNormal+AD4APA-span
style+AD0-'font-size:10.0pt'+AD4-(a)+ADw-/span+AD4APA-/p+AD4-
+ADw-/td+AD4- +ADw-td valign+AD0-top style+AD0-'padding:0in 0in 0in
0in'+AD4- +ADw-p class+AD0-MsoNormal+AD4APA-span
style+AD0-'font-size:10.0pt'+AD4-a non-refundable fee of +AFsAKgBd-
for the first Proposed Target (+IBwAPA-u+AD4-First Upfront
Fee+ADw-/u+AD4gHQ-)+ADs- +ADw-/span+AD4APA-/p+AD4- +ADw-/td+AD4-
+ADw-/tr+AD4- +ADw-/table+AD4- +ADw-p
style+AD0-'margin:0in+ADs-margin-bottom:.0001pt'+AD4APA-span
style+AD0-'font-size:4.5pt'+AD4AJg-nbsp+ADsAPA-o:p+AD4APA-/o:p+AD4APA-/span+AD4APA-/p+AD4-
+ADw-table class+AD0-MsoNormalTable border+AD0-0 cellspacing+AD0-0
cellpadding+AD0-0 width+AD0AIg-100+ACUAIg-
style+AD0-'width:100.0+ACUAOw-border-collapse:collapse+ADs-mso-padding-alt:0in
0in 0in 0in'+AD4- +ADw-tr
style+AD0-'mso-yfti-irow:0+ADs-mso-yfti-firstrow:yes+ADs-mso-yfti-lastrow:yes'+AD4-
+ADw-td width+AD0AIg-4+ACUAIg- valign+AD0-top
style+AD0-'width:4.0+ACUAOw-padding:0in 0in 0in 0in'+AD4- +ADw-p
class+AD0-MsoNormal+AD4APA-span
style+AD0-'font-size:10.0pt'+AD4-(b)+ADw-/span+AD4APA-/p+AD4-
+ADw-/td+AD4- +ADw-td valign+AD0-top style+AD0-'padding:0in 0in 0in
0in'+AD4- +ADw-p class+AD0-MsoNormal+AD4APA-span
style+AD0-'font-size:10.0pt'+AD4-a non-refundable fee of +AFsAKgBd-
as set forth in the First Amendment dated February+ACY-nbsp+ADs-28,
2007 to this Agreement (+IBwAPA-u+AD4-Upfront Amendment
Fee+ADw-/u+AD4gHQ-)+ADs- and +ADw-/span+AD4APA-/p+AD4-
+ADw-/td+AD4- +ADw-/tr+AD4- +ADw-/table+AD4- +ADw-p
style+AD0-'margin:0in+ADs-margin-bottom:.0001pt'+AD4APA-span
style+AD0-'font-size:4.5pt'+AD4AJg-nbsp+ADsAPA-o:p+AD4APA-/o:p+AD4APA-/span+AD4APA-/p+AD4-
+ADw-table class+AD0-MsoNormalTable border+AD0-0 cellspacing+AD0-0
cellpadding+AD0-0 width+AD0AIg-100+ACUAIg-
style+AD0-'width:100.0+ACUAOw-border-collapse:collapse+ADs-mso-padding-alt:0in
0in 0in 0in'+AD4- +ADw-t
|
